Fig. 4
From: Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Clinical assessment of PARP inhibitors in cancer therapy. PARP inhibitors based on the concept of synthetic lethality mainly focuses on germline BRCA1/2-mutated tumors. Various PARP inhibitors have been approved by regulatory bodies, such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to treat patients with BRCA-mutated breast, pancreatic, and ovarian cancers. Olaparib is currently undergoing phase 2 clinical trial for the treatment of advanced castration-resistant prostate cancer